AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SERVICES-MISC HEALTH & ALLIED SERVICES, NEC
Mangoceuticals, Inc. Common Stock
XNAS · usd
SIC 8090 · SERVICES-MISC HEALTH & ALLIED SERVICES, NEC
FIGI BBG01CCMRBK4
0.23▼ 0.01 (-5.12%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
0.24
Day's Range
0.23 – 0.26
52-Week Range
0.23 – 2.50
Volume
284.3K
Avg Volume
601.8K
Share Statistics
Shares Outstanding
Employees
—
Exchange
XNAS
Listed
2023-03-21
Share count as of August 13, 2026

Mangoceuticals, Inc. Common Stock (MGRX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Mangoceuticals, Inc. Common Stock (MGRX)
What is Mangoceuticals, Inc. Common Stock's Market Cap?
Mangoceuticals, Inc. Common Stock's Market Cap is $5.0M, based on as-reported figures from SEC (XBRL) filings.
What is Mangoceuticals, Inc. Common Stock's Enterprise Value?
Mangoceuticals, Inc. Common Stock's Enterprise Value is $4.8M, based on as-reported figures from SEC (XBRL) filings.
What is Mangoceuticals, Inc. Common Stock's Price / Sales?
Mangoceuticals, Inc. Common Stock's Price / Sales is 15.9×, based on as-reported figures from SEC (XBRL) filings.
What is Mangoceuticals, Inc. Common Stock's EV / Revenue?
Mangoceuticals, Inc. Common Stock's EV / Revenue is 15.1×, based on as-reported figures from SEC (XBRL) filings.
What is Mangoceuticals, Inc. Common Stock's EV / EBITDA?
Mangoceuticals, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Mangoceuticals, Inc. Common Stock's Revenue (TTM)?
Mangoceuticals, Inc. Common Stock's Revenue (TTM) is $315.2K, based on as-reported figures from SEC (XBRL) filings.
What is Mangoceuticals, Inc. Common Stock's Net Income (TTM)?
Mangoceuticals, Inc. Common Stock's Net Income (TTM) is -$15.1M, based on as-reported figures from SEC (XBRL) filings.
What is Mangoceuticals, Inc. Common Stock's EBITDA?
Mangoceuticals, Inc. Common Stock's EBITDA is -$10.9M, based on as-reported figures from SEC (XBRL) filings.
What is Mangoceuticals, Inc. Common Stock's Diluted EPS (TTM)?
Mangoceuticals, Inc. Common Stock's Diluted EPS (TTM) is -0.70, based on as-reported figures from SEC (XBRL) filings.
What is Mangoceuticals, Inc. Common Stock's EBITDA Margin?
Mangoceuticals, Inc. Common Stock's EBITDA Margin is -3472.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · MGRXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues
Revenues
YoY growth-59.1%-37.9%-10.3%-36.8%
Cost of Revenue
Cost of revenues - related party
Gross profit
% of revenue64.3%42.7%50.3%60.4%
Operating expenses
Selling, General and Administrative Expense
Cost of Revenue
Marketing Expense
Investor relations—
Total Costs and Expenses
Total operating expenses
% of revenue1566.8%4649.5%440.0%9013.9%
Loss from operations
% of revenue-1502.5%-4606.8%-389.7%-8953.5%
Other (income) expense
Interest Expense——
Interest expense - amortization of intangible assets———
Loss from settlement——
Total other expense
Loss before income taxes
Net loss
% of revenue-1909.5%-5014.6%-2934.9%-9043.5%
Net Income Attributable to Noncontrolling Interest
Net loss attributed to Mangoceuticals, Inc.
% of revenue-1909.1%-5014.7%-2935.1%-9042.8%
Earnings Per Share (Diluted)—
Earnings Per Share (Basic)—